Conv. Plasma
Nigella Sativa

All HCQ studies
Meta analysis
study COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Clinical Efficacy of Chloroquine derivatives in COVID-19 Infection: Comparative metaanalysis between the Big data and the real world

Million et al., New Microbes and New Infections, doi:10.1016/j.nmni.2020.100709
Jun 2020  
  Source   PDF   All Studies   Meta AnalysisMeta
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020
*, now known with p < 0.00000000001 from 422 studies, recognized in 42 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,000+ studies for 60+ treatments.
[H]CQ effective and reduces mortality by a factor 3. Meta analysis of 20 studies.
7 meta analyses show significant improvements with hydroxychloroquine for mortality Landsteiner de Sampaio Amêndola, Risch, Risch (B), Stricker, hospitalization Landsteiner de Sampaio Amêndola, recovery Prodromos, combined death/hospitalization/cases Ladapo, and cases García-Albéniz.
Currently there are 39 HCQ for COVID-19 early treatment studies, showing 76% lower mortality [61‑85%], 67% lower ventilation [-710‑99%], 31% lower ICU admission [1‑53%], and 41% lower hospitalization [28‑51%].
Million et al., 6 Jun 2020, peer-reviewed, 14 authors.
This PaperHCQAll
Clinical efficacy of chloroquine derivatives in COVID-19 infection: comparative meta-analysis between the big data and the real world
M Million, P Gautret, P Colson, Y Roussel, G Dubourg, E Chabriere, S Honore, J-M Rolain, F Fenollar, P-E Fournier, J-C Lagier, P Parola, P Brouqui, D Raoult
New Microbes and New Infections, doi:10.1016/j.nmni.2020.100709
In the context of the current coronavirus disease 2019 (COVID-19) pandemic, we conducted a meta-analysis on the effects of chloroquine derivatives in patients, based on unpublished and published reports available publicly on the internet as of 27 May 2020. The keywords 'hydroxychloroquine', 'chloroquine', 'coronavirus', 'COVID-19' and 'SARS-Cov-2' were used in the PubMed, Google Scholar and Google search engines without any restrictions as to date or language. Twenty studies were identified involving 105 040 patients (19 270 treated patients) from nine countries (
Declaration of competing interest The authors declare no competing interests. Funding sources had no role in the design and conduct of the study; collection, management, analysis and interpretation of the data; and preparation, review or approval of the manuscript. Our group used widely available generic drugs distributed by many pharmaceutical companies. Appendix A. Supplementary data Supplementary data to this article can be found online at https://
Andreani, Bideau, Duflot, Jardot, Rolland et al., In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect, Microb Pathog, doi:10.1016/j.micpath.2020.104228
Ashraf, Shokouhi, Shirali, Davari-Tanha, Memar et al., COVID-19 in Iran, a comprehensive investigation from exposure to treatment outcomes, doi:10.1101/2020.04.20.20072421
Barbosa Esper, Da Silva, Costa Oikawa, Castro, Razuk-Filho et al., Empirical treatment with hydroxychloroquine and azithromycin for suspected cases of COVID-19 followed-up by telemedicine
Baudrillard, Simulacres et Simulation
Borba, Val, Sampaio, Alexandre, Melo et al., CloroCovid-19 Team. Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a randomized clinical trial, JAMA Netw Open, doi:10.1001/jamanetworkopen.2020.8857
Borenstein, Hedges, Higgins, Hr, Introduction to meta-analysis, doi:10.1002/9780470743386
Carlucci, Ahuja, Petrilli, Rajagopalan, Jones et al., Hydroxychloroquine and azithromycin plus zinc vs hydroxychloroquine and azithromycin alone: outcomes in hospitalized COVID-19 patients, medRxiv, doi:10.1101/2020.05.02.20080036
Chen, Hu, Zhang, Jiang, Han et al., Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial, medRxiv, doi:10.1101/2020.03.22.20040758
Chen, Liu, Liu, Liu, Xu et al., None, doi:10.3785/j.issn.1008-9292.2020.03.03
Colson, Rolain, Lagier, Brouqui, Raoult, Chloroquine and hydroxychloroquine as available weapons to fight COVID-19, Int J Antimicrob Agents, doi:10.1016/j.ijantimicag.2020.105932
Davido, Lansaman, Bessis, Hydroxychloroquine plus azithromycin: a potential interest in reducing in-hospital morbidity due to COVID-19 pneumonia (HI-ZY-COVID)?, doi:10.1101/2020.05.05.20088757v1
De Novales, Ramírez-Olivencia, Estébanez, De Dios, Herrero et al., Early hydroxychloroquine is associated with an increase of survival in COVID-19 patients: An observational study, Preprints, doi:10.20944/preprints202005.0057.v1
Gautret, Lagier, Parola, Hoang, Meddeb et al., Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial
Geleris, Sun, Platt, Zucker, Baldwin et al., Observational study of hydroxychloroquine in hospitalized patients with Covid-19, N Engl J Med, doi:10.1056/NEJMoa2012410
Guerin, Lardenois, Levy, De Andreis, Sarrazin et al., + hydroxychloroquine). Rapport d'expérience de médecins de terrain Recommandations diagnostiques et thérapeutiques à l'usage de leurs consoeurs et confrères
Huang, Li, Xiao, Liang, Pang et al., Preliminary evidence from a multicenter prospective observational study of the safety and efficacy of chloroquine for the treatment of COVID-19, medRxiv, doi:10.1101/2020.04.26.20081059
Huang, Tang, Pang, Li, Ma et al., Treating COVID-19 with chloroquine, J Mol Cell Biol, doi:10.1093/jmcb/mjaa014
Lagier, Aubry, Delord, Michelet, Tissot-Dupont et al., From expert protocols to standardized management of infectious diseases, Clin Infect Dis
Lagier, Fenollar, Lepidi, Roch, Million et al., Treatment of classic Whipple's disease: from in vitro results to clinical outcome, J Antimicrob Chemother
Lagier, Million, Gautret, Colson, Cortaredona et al., Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: A retrospective analysis, Travel Med Infect Dis, doi:10.1016/j.tmaid.2020.101791
Lagier, Million, Raoult, Bouillabaisse or fish soup: the limitations of meta-analysis confronted to the inconsistency of fecal microbiota transplantation studies, Clin Infect Dis, doi:10.1093/cid/ciz707
Magagnoli, Narendran, Pereira, Cummings, Hardin et al., Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19, medRxiv, doi:10.1101/2020.04.16.20065920
Mahevas, Tran, Roumier, Chabrol, Paule et al., No evidence of clinical efficacy of hydroxychloroquine in patients hospitalized for COVID-19 infection with oxygen requirement: results of a study using routinely collected data to emulate a target trial, medRxiv, doi:10.1101/2020.04.10.20060699
Mehra, Desai, Ruschitzka, Patel, Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis, Lancet. Published online, doi:10.1016/S0140-6736(20)31180-6
Melenotte, Protopopescu, Million, Edouard, Carrieri et al., Clinical features and complications of Coxiella burnetii infections from the French National Reference Center for Q fever, JAMA Netw Open
Million, Lagier, Gautret, Colson, Fournier et al., Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France, Travel Med Infect Dis, doi:10.1016/j.tmaid.2020.101738
Million, Raoult, Relevance of medical big data analysis depends on clinical accuracy: the Q fever paradigm, Clin Infect Dis
Muchielli, Le, De, Mucchielli, None
Rosenberg, Dufort, Udo, Wilberschied, Kumar et al., Association of treatment with hydroxychloroquine or azithromycin with in-Hospital mortality in patients with COVID-19 in New York State, JAMA, doi:10.1001/jama.2020.8630
Shabrawishi, Naser, Aldobyany, Negative nasopharyngeal SARS-CoV-2 PCR conversion in Response to different therapeutic interventions, doi:10.1101/2020.05.08.20095679v1
Shabrawishi, Naser, Alwafi, Aldobyany, Touman, Negative nasopharyngeal SARS-CoV-2 PCR conversion in Response to different therapeutic interventions, medRxiv, doi:10.1101/2020.05.08.20095679
Singh, Khan, Chowdhry, Chatterjee, Outcomes of hydroxychloroquine treatment among hospitalized COVID-19 patients in the United States-real-world evidence from a federated electronic medical record network, medRxiv, doi:10.1101/2020.05.12.20099028
Tan, Wang, Zhang, Ding, Huang et al., Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study, Signal Transduct Target Ther, doi:10.1038/s41392-020-0148-4
Tang, Cao, Han, Wang, Chen et al., Hydroxychloroquine in patients with COVID-19: an open-label, randomized, controlled trial, doi:10.1101/2020.04.10.20060558
Tang, Cao, Han, Wang, Chen et al., Hydroxychloroquine in patients with COVID-19: an open-label, randomized, controlled trial, doi:10.1101/2020.04.10.20060558
Tang, Cao, Han, Wang, Chen et al., Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial, BMJ, doi:10.1136/bmj.m1849
Yanturali, Aksay, Demir, Atilla, Massive hydroxychloroquine overdose, Acta Anaesthesiol Scand
Yu, Li, Hydroxychloroquine application is associated with a decreased mortality in critically ill patients with COVID-19, medRxiv, doi:10.1101/2020.04.27.20073379
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop